These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 15543200

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, Olavarria E, Goldman JM, Rahemtulla A.
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [Abstract] [Full Text] [Related]

  • 3. Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients.
    Krejci M, Hajek R, Buchler T, Krivanova A, Svobodnik A, Pour L, Adam Z, Mayer J, Vorlicek J.
    Neoplasma; 2007 Feb; 54(2):143-8. PubMed ID: 17319788
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
    O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V, Naresh K, Lampert I, Samson D, Narat S, Kanfer E, Olavarria E, Apperley JF, Rahemtulla A.
    Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
    [Abstract] [Full Text] [Related]

  • 6. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I, Vignetti M, Meloni G, Vegna ML, Scimè R, Tringali S, Amaddii G, Coser P, Tribalto M, Raimondi R, Bergonzi C, Sajeva MR, Sica S, Ferrando F, Messina G, Mandelli F.
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [Abstract] [Full Text] [Related]

  • 7. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP.
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [Abstract] [Full Text] [Related]

  • 8. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
    Björkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, Marcus R, Boogaerts M, Alegre A, Remes K, Cornelissen JJ, Bladé J, Lenhoff S, Iriondo A, Carlson K, Volin L, Littlewood T, Goldstone AH, San Miguel J, Schattenberg A, Gahrton G.
    Bone Marrow Transplant; 2001 Mar; 27(5):511-5. PubMed ID: 11313685
    [Abstract] [Full Text] [Related]

  • 9. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
    Wechalekar A, Amato D, Chen C, Keith Stewart A, Reece D.
    Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
    [Abstract] [Full Text] [Related]

  • 10. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [Abstract] [Full Text] [Related]

  • 11. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma.
    Elice F, Raimondi R, Tosetto A, D'Emilio A, Di Bona E, Piccin A, Rodeghiero F.
    Am J Hematol; 2006 Jun; 81(6):426-31. PubMed ID: 16680735
    [Abstract] [Full Text] [Related]

  • 12. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
    Papajik T, Raida L, Faber E, Vondrakova J, Prochazka V, Kubova Z, Skoumalova I, Jarosova M, M LK, Paucek B, Myslivecek M, Neoral C, Oral I, Jarkovsky J, Dusek L, Indrak K.
    Neoplasma; 2008 Jun; 55(3):215-21. PubMed ID: 18348654
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
    Eom KS, Min CK, Lee S, Kim YJ, Kim SY, Kim HJ, Lee JW, Min WS, Kim CC.
    Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727
    [Abstract] [Full Text] [Related]

  • 14. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
    Harousseau JL, Avet-Loiseau H, Attal M, Charbonnel C, Garban F, Hulin C, Michallet M, Facon T, Garderet L, Marit G, Ketterer N, Lamy T, Voillat L, Guilhot F, Doyen C, Mathiot C, Moreau P.
    J Clin Oncol; 2009 Dec 01; 27(34):5720-6. PubMed ID: 19826130
    [Abstract] [Full Text] [Related]

  • 15. Retrospective analysis of the results of high-dose chemotherapy with the support of autologous blood stem cells in patients with multiple myeloma. The experience of a single centre.
    Kořen J, Spička I, Straub J, Vacková B, Trnková M, Pohlreich D, Pytlík R, Trněný M.
    Prague Med Rep; 2010 Dec 01; 111(3):207-18. PubMed ID: 20946721
    [Abstract] [Full Text] [Related]

  • 16. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW.
    Biol Blood Marrow Transplant; 2007 Aug 01; 13(8):925-31. PubMed ID: 17640596
    [Abstract] [Full Text] [Related]

  • 17. Clinical effects of autologous stem cell transplantation as consolidation treatment in 70 multiple myeloma patients: a case-controlled study.
    Zhou LL, Yuan ZG, Fu WJ, Xi H, Zhang CY, Lan HF, Zhang X, Chen Y, Liu WY, Hou J.
    Chin Med J (Engl); 2011 Oct 01; 124(19):2975-80. PubMed ID: 22040538
    [Abstract] [Full Text] [Related]

  • 18. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE, Thomas W, Defor TE, Weisdorf DJ, Burns LJ.
    Biol Blood Marrow Transplant; 2007 Apr 01; 13(4):486-92. PubMed ID: 17382255
    [Abstract] [Full Text] [Related]

  • 19. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
    Cheema PK, Zadeh S, Kukreti V, Reece D, Chen C, Trudel S, Mikhael J.
    Biol Blood Marrow Transplant; 2009 Jun 01; 15(6):686-93. PubMed ID: 19450753
    [Abstract] [Full Text] [Related]

  • 20. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
    Inamoto Y, Kurahashi S, Imahashi N, Fukushima N, Adachi T, Kinoshita T, Tsushita K, Miyamura K, Naoe T, Sugiura I.
    Am J Hematol; 2009 May 01; 84(5):283-6. PubMed ID: 19338045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.